SOCIETY ON SARCOPENIA, CACHEXIA, & WASTING DISORDERS (SCWD)
The 18th International Conference of the SCWD 2025
11–13 December 2025, Rome, Italy.
New record: Over 200 abstracts received!
Discover the latest breakthroughs in cachexia, sarcopenia & muscle-wasting at the 18th International SCWD Conference.
SOCIETY ON SARCOPENIA, CACHEXIA, & WASTING DISORDERS (SCWD)
Driving Innovation in Research,
Education and Clinical Excellence Worldwide
From Basic Science to Clinical Management of Sarcopenia, Cachexia and Wasting
Multidisciplinary Approaches to Improve Patients’ Outcomes
The Society on Sarcopenia, Cachexia, and Wasting Disorders (SCWD) focuses on muscle wasting across a number of medical conditions and strives to enhance global health by advancing cutting-edge research that informs effective policies and practices for medical professionals and healthcare stakeholders.
Our mission is to address the challenges of cachexia (including cancer cachexia), sarcopenia, and wasting disorders involving all stakeholders to improve the lives of patients with cachexia and sarcopenia worldwide.
Explore the latest programs and information about Sarcopenia, Cachexia, & Wasting Disorders
Stay Involved
SCIENCE & RESEARCH
Your Area of Expertise
Explore our Programs and Resources
- 🗓️ Date: 2025-11-06
- 📰 Journal: Journal Of Cachexia Sarcopenia And Muscle
- 🗓️ Date: 2025-11-06
- 📰 Journal: Nature Reviews Endocrinology
- 🗓️ Date: 2025-11-05
- 📰 Journal: Clinical Nutrition
- 🗓️ Date: 2025-11-04
- 📰 Journal: Journal Of Cachexia Sarcopenia And Muscle
- 🗓️ Date: 2025-11-04
- 📰 Journal: Journal Of Cachexia Sarcopenia And Muscle
- 🗓️ Date: 2025-11-04
- 📰 Journal: Hematological Oncology
Therapeutic potential of FGF19 in combatting osteosarcopenia: effects on muscle strength and bone health in aged male mice.
Efficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial.
The mitochondrial-targeted antioxidant SkQ1 prevents skeletal muscle mitochondrial-apoptotic but not necroptotic signalling during ovarian cancer.
Reply – letter to the editor: The JOHAS (Judgement of Objective Hypersteatosis and Atrophy in Sarcopenia) index; an index for sarcopenia or low muscle mass?
Our Dedication to Advancing Science
The Journal of Cachexia, Sarcopenia and Muscle is committed to pioneering research that addresses the critical challenges of cachexia and sarcopenia. By publishing the finest work from across the life sciences, we unite experts to push the boundaries of knowledge and improve patient care. Discover how our journal can support your research through opportunities for publication and collaboration.
Register Now!
Embrace this opportunity to redefine the field and create lasting impact in the lives of patients worldwide.





